Skip to main content
    P

    Pharming Group NV (PHAR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.59
    -0.01 (-0.08%)

    Market Cap: $891.80M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Pharming Group NV (PHAR) Financials: Revenue, Profit and Cash Flow

    Updated Oct 27, 2026. Financial statements from company filings, amounts in US dollars.

    Pharming Group NV reported revenue of $376.13M for the fiscal year ended Dec 31, 2025, up 26.6% from the year before. That year, net income was $2.85M with a net margin of 0.8%, operating cash flow was $54.71M and free cash flow was $53.95M. The quarter ended Sep 30, 2026 had revenue of $117.56M and net income of $22.43M.

    Revenue and Margins

    The operating margin was 5.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $16.69M, a compound annual rate of 41.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$376.13M+26.6%87.9%5.6%0.8%
    Dec 2024$297.20M+21.1%88.1%-1.2%-4.0%
    Dec 2023$245.32M+19.3%89.7%-9.1%-4.3%
    Dec 2022$205.62M+3.4%91.5%4.8%6.7%
    Dec 2021$198.87M-6.3%89.4%9.6%8.0%
    Dec 2020$212.17M+12.0%88.9%35.9%17.8%
    Dec 2019$189.39M+22.5%87.4%36.0%21.4%
    Dec 2018$154.58M+43.8%83.6%28.1%18.5%
    Dec 2017$107.52M+544.1%86.1%24.4%-85.1%
    Dec 2016$16.69MN/A70.5%-72.7%-110.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 197.1% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$376.13M$297.20M$245.32M$205.62M$198.87M$212.17M$189.39M$154.58M$107.52M$16.69M
    Cost of revenue$45.50M$35.40M$25.21M$17.56M$21.14M$23.54M$23.93M$25.37M$14.93M$4.93M
    Gross profit$330.63M$261.80M$220.10M$188.06M$177.73M$188.63M$165.46M$129.20M$92.59M$11.77M
    Research and development$100.37M$83.15M$68.91M$52.53M$70.37M$38.52M$31.79M$33.04M$22.38M$16.18M
    Operating income$20.88M-$3.67M-$22.29M$9.86M$19.01M$76.26M$68.25M$43.46M$26.29M-$12.14M
    Net income$2.85M-$11.84M-$10.55M$13.67M$16.00M$37.75M$40.56M$28.59M-$91.47M-$18.44M
    EBITDA$34.78M$16.32M$9.88M$33.53M$48.78MN/A$71.46MN/AN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$117.56M$90.21M$72.45M$106.50M$97.29M$93.22M$79.09M$92.70B$74.85M$74.09M$55.59M$81.87M
    Gross profit$102.19M$75.67M$65.80M$85.40M$90.22M$84.25M$70.77M$80.50B$68.03M$66.11M$47.20M$74.71M
    Operating income$29.89M-$111.00K-$5.29M$2.00M$15.75M$9.00M-$7.43M$6.60B$3.33M-$3.12M-$16.31M$604.93K
    Net income$22.43M$1.64M-$5.21M$5.30M$7.55M$4.69M-$14.72M$2.90B-$1.03M-$1.22M-$12.45M-$2.72M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $101.42M by $44.60M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$499.81M$414.18M$462.85M$425.80M$450.44M$342.55M$255.91M$214.48M$199.38M$133.34M
    Current assets$299.38M$288.32M$316.34M$277.50M$282.80M$215.47M$119.44M$115.44M$105.87M$65.41M
    Cash and equivalents$146.02M$56.89M$61.74M$207.34M$217.59M$167.94M$74.35M$80.31M$70.37M$33.54M
    Total liabilities$222.79M$185.27M$244.07M$221.16M$231.73M$192.39M$138.53M$152.73M$176.82M$104.45M
    Short-term debt$8.71M$7.45M$5.44M$5.23M$4.87M$3.28M$53.31M$40.61M$22.66M$26.40M
    Long-term debt$92.72M$78.15M$136.60M$131.62M$122.65M$121.93M$0$37.27M$58.68MN/A
    Shareholder equity$277.02M$228.91M$218.78M$204.64M$218.71M$150.16M$117.39M$61.75M$16.11M$27.47M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$496.64M$467.98M$489.37M$499.81M$403.57M$446.26M$403.18M$399.99M$425.51M$388.27M$409.29M$461.42M
    Total liabilities$205.40M$197.49M$220.41M$222.79M$178.15M$206.71M$187.89M$178.92M$199.72M$182.02M$218.44M$242.24M
    Cash and equivalents$189.56M$158.28M$53.10M$146.02M$112.75M$94.82M$60.09M$54.94M$60.66M$44.01M$48.09M$61.74M
    Shareholder equity$291.24M$270.49M$268.96M$277.02M$225.42M$239.55M$214.00M$221.06M$225.79M$206.24M$190.85M$219.19M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 98.6% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$54.71M-$1.79M-$17.30M$22.46M$37.84M$83.63M$74.15M$46.34M$45.84M-$10.52M
    Capital expenditures$755.00K$796.00K$1.46M$1.98M$16.72M$15.30M$25.45M$4.31M$7.25M$1.59M
    Free cash flow$53.95M-$2.59M-$18.77M$20.48M$21.13M$68.33M$48.70M$42.03M$38.59M-$12.11M
    Investing cash flow$26.25M$31.62M-$129.39M$5.32M-$21.30M-$15.63M-$28.26M-$4.31M-$7.25M-$60.45M
    Financing cash flow$1.50M-$34.41M-$1.04M-$4.98M-$27.95M$60.69M-$63.47M-$20.55M-$3.91M$70.81M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$32.55M-$12.68M$1.95M$10.71M$32.03M$11.74M$232.00K$9.33M$9.74M-$13.22M-$7.65M$12.18M
    Capital expenditures$279.95K$82.45K$238.00K$269.00K$70.00K$128.00K$288.00K$136.00K$366.00K$214.00K$80.00K$331.44K
    Free cash flow$32.27M-$12.77M$1.71M$10.44M$31.96M$11.62M-$56.00K$9.20M$9.38M-$13.44M-$7.73M$11.85M
    Last 12 quarters

    Frequently Asked Questions About PHAR

    What is Pharming Group NV's annual revenue?

    Pharming Group NV reported revenue of $376.13M for the fiscal year ended Dec 31, 2025.

    How fast is Pharming Group NV's revenue growing?

    Revenue was up 26.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 22.3%.

    Is Pharming Group NV profitable?

    Yes. Pharming Group NV reported net income of $2.85M for the fiscal year ended Dec 31, 2025, with a net margin of 0.8%.

    How much free cash flow does PHAR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $54.71M minus capital expenditures of $755.00K produced free cash flow of $53.95M.

    How much debt does Pharming Group NV have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $92.72M, short-term debt of $8.71M and cash and equivalents of $146.02M.